Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Research Council grant · Running

PRIMO Precision Reasoning In Multimodal Ovarian cancer

Coordinator
Institut Regional Du Cancer De Montpellier, France
Runs
1 January 2027 to 30 June 2028
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101334828

What the project is doing

In the project's own words, from its summary on CORDIS.

Ovarian cancer remains the deadliest gynecologic malignancy largely because critical treatment decisions are made under persistent uncertainty. Multidisciplinary tumour boards (MDTs) must choose between competing strategies—primary surgery or neoadjuvant chemotherapy, and alternative maintenance therapies—based on fragmented clinical, imaging and pathology information. Current AI systems, including emerging agentic systems, mainly retrieve guidelines or summarize records; they do not embed a disease-specific computational model of the patient and therefore cannot deliver calibrated prognosis or transparent simulation.

PRIMO addresses this gap by developing the first clinical-grade AI decision-support system dedicated to MDT in ovarian cancer. Building directly on the ERC-funded MR-O-MICS project, PRIMO leverages ONCO-IMAGE technologies enabling automated tumour segmentation, quantitative tumour burden estimation and validated morpho-radiomic survival modelling from routine CT and MRI. In collaboration with Synagen, co-founded by ERC laureate Prof.

Jakob Kather, PRIMO will integrate imaging, clinical and molecular data into a unified computational patient model capable of generating survival predictions and treatment-aware simulations. The Proof of Concept will deploy and validate PRIMO in real MDT workflows under shadow conditions, demonstrating its ability to provide actionable, quantitative decision support. By transforming fragmented multimodal data into a coherent, predictive and clinically usable model, PRIMO has the potential to fundamentally shift MDT decision-making from qualitative consensus toward quantitative, reproducible and patient-specific treatment selection, with broad applicability across oncology.

Topics

Who is involved

OrganisationCityCountryRole
Institut Regional Du Cancer De MontpellierMontpellier Cedex 5FranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI